BioCorRx Reports 50.6% Revenue Decline and $1M Net Loss in Q2 2026

BioCorRx Inc. reported its financial results for the second quarter of 2026, revealing a significant decline in revenue and ongoing operational challenges. The company generated net revenues of $87,970 for the three months ended June 30, 2026, a decrease of 50.6% compared to $178,238 in the same period last year. For the six months ended June 30, 2026, total revenues were $167,038, down 46.7% from $313,137 in the prior year. The decline in revenue is attributed primarily to reduced distribution sales of its Lucemyra product and a decrease in the number of patients treated at licensed clinics.

Operating expenses for the second quarter totaled $1,553,508, slightly lower than the $1,592,158 reported in the same quarter of 2025. The decrease was driven by reduced accounting and legal fees, consulting expenses, and depreciation costs, which were partially offset by increased research and development expenses. The company reported a net loss of $1,001,706 for the quarter, an improvement from a net loss of $1,377,276 in the prior year. For the six-month period, the net loss was $2,012,798, compared to $2,229,040 in the same period of 2025.

In terms of strategic developments, BioCorRx has made significant moves to strengthen its position in the market. On March 26, 2026, the company acquired an additional 12.15% ownership interest in its subsidiary, BioCorRx Pharmaceuticals Inc., in exchange for 2,263,371 shares of common stock. This acquisition is part of a broader strategy to enhance its research and development capabilities, particularly for its BICX104 product, an implantable naltrexone pellet aimed at treating opioid use disorder. The company also received a substantial grant of $11,029,977 from the National Institute on Drug Abuse to support ongoing research for BICX104.

Operationally, BioCorRx reported a working capital deficit of $8,231,326 as of June 30, 2026, with cash reserves dwindling to $21,237. The company has relied heavily on private placements and shareholder advances to fund its operations, raising $650,000 through common stock subscriptions in the first half of 2026. However, the company faces substantial doubt about its ability to continue as a going concern without raising additional capital. The management has indicated that it will need to implement cost-cutting measures or extend payables if sufficient funding is not secured.

Looking ahead, BioCorRx's management remains focused on securing additional financing to support its operations and development activities. The company is actively pursuing opportunities to raise capital through private placements of equity and debt securities. However, there is no assurance that these funds will be available on favorable terms or that they will be sufficient to sustain operations. The company’s future performance will depend on its ability to navigate these financial challenges while continuing to advance its product development initiatives.